{"classes":[{"categories":[{"measurements":[{"comment":"A confidence interval cannot be computed when the rate is zero, i.e. when there are zero events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG001","lowerLimit":"0.4","upperLimit":"50.3","value":"14.3"},{"groupId":"OG002","lowerLimit":"2.1","upperLimit":"37.6","value":"14.3"},{"groupId":"OG003","lowerLimit":"2","upperLimit":"19.3","value":"7.9"},{"groupId":"OG004","lowerLimit":"5.4","upperLimit":"29.5","value":"15.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"33"}],"units":"Participants"}],"description":"Distant metastases is defined as the appearance after protocol therapy of cancer deposits characteristic of metastatic dissemination from non-small cell lung cancer. Distant metastases progression was assessed using the cumulative incidence method to estimate the 2-year failure rate. Arms were not compared/tested.","dispersionType":"95% Confidence Interval","groups":[{"description":"SBRT delivered in 5 fractions of 10.0 Gy/fraction over 1.5 to 2 weeks for a total of 50.0 Gy","id":"OG000","title":"Level 5: 10.0 Gy/FX"},{"description":"SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy","id":"OG001","title":"Level 6: 10.5 Gy/FX"},{"description":"SBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy","id":"OG002","title":"Level 7: 11.0 Gy/FX"},{"description":"SBRT 57.5 Gy\n\nSBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy","id":"OG003","title":"Level 8: 11.5 Gy/FX"},{"description":"SBRT 60.0 Gy\n\nSBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy","id":"OG004","title":"Level 9: 12.0 Gy/FX"}],"paramType":"NUMBER","populationDescription":"All eligible patients who started study treatment","reportingStatus":"POSTED","timeFrame":"From randomization to date of death, distant failure or last follow-up. Analysis occurs after all patients have been potentially followed for 24 months, approximately 7.5 years from the start of the study.","title":"Distant Metastases","type":"SECONDARY","unitOfMeasure":"percentage of participants"}